

Dear Editor,

Thank you for your time, editorial work and comments for our invited manuscript 57740 entitled, « *Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells* " that is under revision in *World Journal of Stem Cells*. We really appreciated your invitation to contribute to the field as a leading group with high expertise in the immune biology of MSCs. We would also like to thank through you the reviewers for their comments, suggestions, and corrections.

Please find, hereafter, a revised version of the manuscript as requested by the reviewers as well as responses to their comments (in a separate file). Changes inside the manuscript were highlighted in red. As requested by the Editorial Office Director, we have added five figures inside the manuscript. For your information, we do not have an Audio Core tip, and therefore we have only provided a normal core tip.

We hope this revision will meet your agreement as well as that of the reviewers and look forward to hearing from you in the near future. Thank you for considering our revised submission.

Yours sincerely,

Reviewer #1:

- Scientific Quality: Grade C (Good)
- Language Quality: Grade B (Minor language polishing)
- Conclusion: Accept (General priority)
- Specific Comments to Authors:

In this MS, the authors investigated the novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells. Some problems existed.

1. The language needs to be improved because of some grammar, spelling, and punctuation mistakes.

We thank the reviewer for this opportunity to increase the language quality of our work. A native-English speaker has thus edited the manuscript.

2. VEGF: PLEASE give the full name to this abbreviation at the first time of use. For all other abbreviations, the same rule applies. Such as TLR3, BM-, WJ- , AT-MSC

We thank the reviewer for this opportunity to increase the clarity of our work. We have thus introduced the full names of the abbreviations when it was required.

3. In the inflammatory preconditioning section, the paragraph is too long. Please separate it to several paragraphs with subtitles.

We thank the reviewer for this opportunity to increase the quality of our work. We have thus separated the inflammatory preconditioning section into several paragraphs with subtitles.

4. In the section of cell-free based therapeutics, please give a citation for the following sentence: Several scientific societies propose to optimize the methods and harmonize the criteria that identify and characterize EVs from MSCs.

As requested, we have added the citation “97” to this sentence.

Witwer KW, Van Balkom BWM, Bruno S, Choo A, Dominici M, Gimona M, Hill AF, De Kleijn D, Koh M, Lai RC, Mitsialis SA, Ortiz LA, Rohde E, Asada T, Toh WS, Weiss DJ, Zheng L, Giebel B, Lim SK. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles 2019; 8: 1609206 [PMID: 31069028 DOI: 10.1080/20013078.2019.1609206]